---
schema_version: "secwatch.filing_event.v1"
accession: "0001662774-24-000010"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:57:32.068095+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics Q3 net loss $5.5M; Phase 3 NEAT enrollment at 32 patients

## Summary
- Phase 3 NEAT trial enrolled 32 patients; on track to complete enrollment in Q2 2025 with topline results in Q4 2025.
- Cash, equivalents, and short-term investments of $47.8M; runway expected into 2026 through topline results.
- Net loss of $5.5M ($0.13 per share) for Q3 2024; R&D expenses $4.9M, G&A expenses $3.6M.
- Plans to initiate a Phase 2 Duchenne muscular dystrophy study in 2025.
- Identified 11 potential new rare disease indications for EryDex beyond A-T and DMD.

## SEC filing metadata
- accession: 0001662774-24-000010
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000166277424000010/0001662774-24-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000166277424000010/qncx-20241113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001662774-24-000010
- JSON: https://secwatch.observer/filing/0001662774-24-000010.json
- Plain text: https://secwatch.observer/filing/0001662774-24-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.